In this context, the present systematic review and meta-analysis1 provide the most comprehensive evaluation to date of prostate cancer–specific mortality (CSM) and overall mortality (OM) in immunocompromised patients, including more than 3.4 million individuals. By stratifying outcomes according to the type of immunosuppression, the study offers clinically relevant insights that challenge long-standing paradigms.
Key Findings
- Overall, immunocompromised patients did not show a significantly higher CSM compared with immunocompetent controls.
- Solid organ transplant recipients exhibited CSM rates comparable to those of the general population, despite a consistently higher OM.
- In contrast, patients living with HIV had a significantly higher CSM, suggesting a distinct biological or clinical behavior of PCa in this subgroup.
- Across all immunocompromised categories, OM was substantially higher, reflecting the burden of comorbidities and non–cancer-related mortality.
- Immunosuppression is not a uniform clinical entity and should not automatically justify treatment escalation or de-escalation.
These findings support a differentiated approach to PCa management based on the underlying immunosuppressive condition. For transplant recipients, standard guideline-based treatment strategies appear appropriate, as cancer-specific outcomes are not compromised. Conversely, HIV-infected patients may require closer surveillance and potentially more aggressive treatment strategies due to a higher risk of PCa-related mortality.
Written by: Francesco Di Bello, MD, University of Naples Federico II, Naples, Italy; Fundaciò Puigvert, Barcelona, Spain
Reference:
Read the Abstract